May Microbiome Modulation. Assaf Oron, CBO Biomed Conference Tel Aviv, May 2017

Transcription

1 May 2017 Microbiome Modulation Assaf Oron, CBO Biomed Conference Tel Aviv, May 2017

2 Microbiome A revolutionary cure Linda, lives in California 2010 Was treated with antibiotics due to a severe urinary tract infection Soon after Tested positive for C. Diff Multiple Antibiotics Flagyl, Vanomycin Vitamin supplements, probiotics I lost 68 pounds in 4 years 2014 Linda underwent Fecal Microbiota Transplantation (FMT) and was cured

3 Microbiome A revolutionary cure

4 Our Microbiome We have > X100 microbial genes than human genes Our Microbiome Microbials (mainly bacteria) that reside in/on our body Human DNA 99.9% identical Microbiome DNA 80-90% identical

5 The Microbiome plays a vital role and interventions are paving a path forward Obesity alters gut microbial ecology Google trends Microbiome Gut Bacteria Shakes up Cancer Research Microbiome Bacterial imbalance in Crohn s disease Microbial cocktails join fecal transplants in IBD

6 Microbiome Can it cure obesity? Microbiota Transplant Microbiota Transplant

7 Microbiome Industry License to C. Diff. Phase II candidate and other - $120M upfront + $660M MS + Royl. Vedanta license IBD Pre-clinical product to Janssen

8 BiomX Mission We develop novel therapeutics to alleviate microbiome-related diseases using our 3-tier Microbiome Modulation Platform, devised by world-leading scientists

9 BiomX at a Glance Establishment Founded 2015 Based in Israel >20 Employees Investors Pipeline P. acnes Pre-Clinical IBD Pre-Clinical GI tract associated Cancers Phage Discovery Immune oncology Target Discovery Technology Our 3-Tier Microbiome Modulation Platform: Target Bacteria Discovery Microbiome Modulation Drug Development Scientific Founders Prof. Rotem Sorek, Weizmann Institute - Expert in phage biology Dr. Expert in phage biology, Leader in microbiome research Prof. Timothy K, Lu, MIT - Leader in phage engineering therapeutics Financing Completed $24 M series A

10 Groundbreaking research from BiomX founders has unlocked a Broad microbiome drug potential Dr. Eran Elinav MD, PhD Developed unique mouse models and humanized mice World leader in microbiome research Published in Cell, Science Prof. Timothy K. Lu MD, PhD Extensive work with engineered bacteriophage therapeutics for antibiotic-resistant infection World leader in synthetic biology Published in Nature, Science Prof. Rotem Sorek PhD Expert in phage biology and massive genome analyses World leader in CRISPR research Published in Nature, Science

11 Our 3-Tier Microbiome Modulation Platform Target Bacteria Discovery Microbiome Modulation Product Development

12 Target bacteria discovery Target Bacteria Discovery 100 trillion bacteria

13 Target bacteria discovery Target Bacteria Discovery >1,000 species

14 Target bacteria discovery Target Bacteria Discovery 10,000 s strains

15 Target bacteria discovery Target Bacteria Discovery Add Stimuli

16 Target bacteria discovery Target Bacteria Discovery X

17 Target bacteria discovery Eradicate Phage Discovery Microbiome Modulation X A proprietary high throughput platform for natural and synthetic phage discovery

18 Bacteriophage cocktails as therapeutic agent 1 LOCATE 2 INJECT 3 INFECT Viral Genome 4 MULTIPLY 5 ASSEMBLE 6 A BACTERIOPHAGE IS A VIRUS THAT INFECTS ONLY A SPACIFIC BACTERIUM 3 Tail Fiber 6 ERADICATE 7 SEEK 5 4

19 Target bacteria discovery Eradicate Phage Discovery Microbiome Modulation X A proprietary high throughput platform for natural and synthetic phage discovery Add Bacteria Culturing, stability, reproducibility

20 Target bacteria discovery Product Development In Vivo testing Advanced In-Vitro/Ex-Vivo testing Process development Formulation Production Regulatory Phage formulation in collaboration with Takeda BX001 spray dried Dissolution Formulation Dissolution

21 End-to-end Microbiome Modulation Platform Target Bacteria Discovery Microbiome Modulation Product Development

22 A broad & diverse pipeline Step 1 TARGET DISCOVERY Step 2 MICROBIOME MODULATION Step 3 PRE-CLINICAL DEVELOPMENT Step 4 CLINICAL DEVELOPMENT ACNE BX001 IBD (INFLAMMATORY BOWEL DISEASE) BX002 GI associated Cancers Harnessing Synthetic Biology IMMUNO-ONCOLOGY Checkpoint Inhibitors

23 Acne BX001 $5.1B Acne Therapy Market A topical gel of a proprietary phage cocktail BX001 on a lawn of P. acnes 1 2 Target what s needed, not damaging good bacteria Address antibiotic resistance An opportunity for novel alternatives to antibiotics 3 Black Where gel with BX001 was applied Red Area of phage activity (eradicated P.acnes) Self replicating Increased activity in site * 2017 total acne therapy market forecast, Acne Treatment Market: Global Industry Analysis and Forecast, , Persistence Market Research

24 Density (OD 600nm) IBD BX002 $8B IBD therapy market A phage cocktail eradicating IBD inducing bacteria Clear evidence that gut bacteria impacts IBD BX002 eradicated specific IBD inducing bacteria Time (Hrs) Red Control, only bacteria Green Bacteria + BX002 Bacteria eradicated: 1 2 Novel, specific IBD induction path Demonstrate IBD induction in-vivo 3 Antibiotic resistant * CCFA Crohn s & Colitis Foundation of America. Visiongain IBD report

25 May 2017 Thank You! Visit us at